2.53
price up icon4.12%   0.10
after-market アフターアワーズ: 2.42 -0.11 -4.35%
loading
前日終値:
$2.43
開ける:
$2.42
24時間の取引高:
133.00K
Relative Volume:
0.33
時価総額:
$67.89M
収益:
$9.94M
当期純損益:
$-144.49M
株価収益率:
-0.4521
EPS:
-5.5956
ネットキャッシュフロー:
$-103.90M
1週間 パフォーマンス:
+0.00%
1か月 パフォーマンス:
+29.08%
6か月 パフォーマンス:
-50.68%
1年 パフォーマンス:
+2.02%
1日の値動き範囲:
Value
$2.42
$2.59
1週間の範囲:
Value
$2.06
$2.6198
52週間の値動き範囲:
Value
$1.43
$8.17

Syros Pharmaceuticals Inc Stock (SYRS) Company Profile

Name
名前
Syros Pharmaceuticals Inc
Name
セクター
Healthcare (1182)
Name
電話
617-744-1340
Name
住所
35 CAMBRIDGE PARK DRIVE, CAMBRIDGE
Name
職員
68
Name
Twitter
@syrospharma
Name
次回の収益日
2024-10-31
Name
最新のSEC提出書
Name
SYRS's Discussions on Twitter

Syros Pharmaceuticals Inc Stock (SYRS) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2020-11-04 アップグレード H.C. Wainwright Neutral → Buy
2020-09-22 開始されました Alliance Global Partners Buy
2020-01-17 ダウングレード Wedbush Outperform → Neutral
2019-03-08 再開されました JMP Securities Mkt Outperform
2019-02-14 再開されました Oppenheimer Outperform
2018-11-05 アップグレード ROTH Capital Neutral → Buy
2018-03-13 繰り返されました Wedbush Outperform
2017-10-31 再開されました Piper Jaffray Overweight
2017-10-23 開始されました ROTH Capital Neutral
2017-08-10 ダウングレード JMP Securities Mkt Outperform → Mkt Perform
すべてを表示

Syros Pharmaceuticals Inc (SYRS) 最新ニュース

pulisher
Nov 04, 2024

Syros Pharmaceuticals (NASDAQ:SYRS) Rating Lowered to Sell at StockNews.com - MarketBeat

Nov 04, 2024
pulisher
Nov 04, 2024

SYRS (Syros Pharmaceuticals) Total Inventories : $0.00 Mil (As of Sep. 2024) - GuruFocus.com

Nov 04, 2024
pulisher
Nov 04, 2024

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Q3 2024 Earnings Call Transcript - MSN

Nov 04, 2024
pulisher
Nov 04, 2024

Syros Pharmaceuticals, Inc. announced that it expects to receive $10 million in funding from Incyte Corporation - Marketscreener.com

Nov 04, 2024
pulisher
Nov 03, 2024

Incyte Corporation and yros Pharmaceuticals Announce Global Target Discovery and Validation Collaboration Focused on Myeloproliferative Neoplasms - Marketscreener.com

Nov 03, 2024
pulisher
Nov 02, 2024

SYRSW (Syros Pharmaceuticals) 5-Year Dividend Growth Rate : 0.00% (As of Jun. 2024) - GuruFocus.com

Nov 02, 2024
pulisher
Nov 02, 2024

Syros Pharmaceuticals Third Quarter 2024 Earnings: US$0.16 loss per share (vs US$1.43 loss in 3Q 2023) - Yahoo Finance

Nov 02, 2024
pulisher
Nov 01, 2024

Syros Pharmaceuticals (NASDAQ:SYRS) Issues Quarterly Earnings Results - MarketBeat

Nov 01, 2024
pulisher
Nov 01, 2024

Earnings call: Syros Pharmaceuticals outlines tamibarotene progress - Investing.com

Nov 01, 2024
pulisher
Nov 01, 2024

Syros Pharmaceuticals Inc (SYRS) Q3 2024 Earnings Call Highlights: Strategic Focus on ... - Yahoo Finance

Nov 01, 2024
pulisher
Nov 01, 2024

Syros Pharmaceuticals (NASDAQ:SYRS) Earns Buy Rating from HC Wainwright - MarketBeat

Nov 01, 2024
pulisher
Nov 01, 2024

Syros Pharmaceuticals Inc (SYRS) Q3 2024 Earnings Call Highlight - GuruFocus.com

Nov 01, 2024
pulisher
Nov 01, 2024

Syros Pharmaceuticals Reports Q3 2024 Financial Results - TipRanks

Nov 01, 2024
pulisher
Oct 31, 2024

Q3 2024 Syros Pharmaceuticals Inc Earnings Call Transcript - GuruFocus.com

Oct 31, 2024
pulisher
Oct 31, 2024

Syros Reports Third Quarter 2024 Financial Results and Provides a Business Update - StockTitan

Oct 31, 2024
pulisher
Oct 31, 2024

Syros Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Oct 31, 2024
pulisher
Oct 25, 2024

Syros Pharmaceuticals (SYRS) Loses -70.55% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - MSN

Oct 25, 2024
pulisher
Oct 25, 2024

Syros Pharmaceuticals (SYRS) Set to Announce Earnings on Thursday - MarketBeat

Oct 25, 2024
pulisher
Oct 25, 2024

Syros Pharmaceuticals' SWOT analysis: stock outlook amid clinical setbacks - Investing.com India

Oct 25, 2024
pulisher
Oct 24, 2024

Syros Pharmaceuticals' SWOT analysis: stock outlook amid clinical setbacks By Investing.com - Investing.com Australia

Oct 24, 2024
pulisher
Oct 23, 2024

Piper Sandler reaffirms overweight rating and $5 PT on Syros Pharmaceuticals stock - Investing.com UK

Oct 23, 2024
pulisher
Oct 15, 2024

Syros Pharmaceuticals (NASDAQ:SYRS) Upgraded by StockNews.com to "Hold" - MarketBeat

Oct 15, 2024
pulisher
Oct 09, 2024

Syros Pharmaceuticals Inc (SYRS) Q2 2024 Earnings Call Highlights: Strategic Focus on ... - Yahoo Finance

Oct 09, 2024
pulisher
Oct 07, 2024

Syros Pharmaceuticals (NASDAQ:SYRS) Downgraded by StockNews.com - MarketBeat

Oct 07, 2024
pulisher
Oct 02, 2024

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Syros Pharmaceuticals, Inc.SYRS - cnhinews.com

Oct 02, 2024
pulisher
Sep 30, 2024

Syros Pharmaceuticals' SWOT analysis: stock faces challenges amid clinical setbacks By Investing.com - Investing.com South Africa

Sep 30, 2024
pulisher
Sep 30, 2024

Syros Pharmaceuticals' SWOT analysis: stock faces challenges amid clinical setbacks - Investing.com India

Sep 30, 2024
pulisher
Sep 24, 2024

575,000 Shares in Spyre Therapeutics, Inc. (NASDAQ:SYRE) Bought by Logos Global Management LP - Defense World

Sep 24, 2024
pulisher
Sep 24, 2024

Ratios Uncovered: Breaking Down Spyre Therapeutics Inc. (SYRE)’s Trailing Twelve Months Metrics - The Dwinnex

Sep 24, 2024
pulisher
Sep 24, 2024

Symphony Environmental Technologies (LON:SYM) Shares Down 13.8% - Defense World

Sep 24, 2024
pulisher
Sep 24, 2024

Spyre Therapeutics Inc.’s results are impressive - US Post News

Sep 24, 2024
pulisher
Sep 24, 2024

Farallon Capital Management LLC Buys Shares of 666,000 Spyre Therapeutics, Inc. (NASDAQ:SYRE) - MarketBeat

Sep 24, 2024
pulisher
Sep 23, 2024

100,000 Shares in Spyre Therapeutics, Inc. (NASDAQ:SYRE) Purchased by Integral Health Asset Management LLC - Defense World

Sep 23, 2024
pulisher
Sep 23, 2024

Spyre Therapeutics (NASDAQ:SYRE) Shares Gap Down to $30.17 - MarketBeat

Sep 23, 2024
pulisher
Sep 23, 2024

Xilio Therapeutics Inc (XLO) rating initates by Chardan Capital Markets - Knox Daily

Sep 23, 2024
pulisher
Sep 23, 2024

Itau Unibanco Holding S.A. Takes $435,000 Position in Ross Stores, Inc. (NASDAQ:ROST) - Defense World

Sep 23, 2024
pulisher
Sep 23, 2024

Avoro Capital Advisors LLC Purchases Shares of 1,839,138 Spyre Therapeutics, Inc. (NASDAQ:SYRE) - Defense World

Sep 23, 2024
pulisher
Sep 23, 2024

Canada Pension Plan Investment Board Acquires 509,700 Shares of Symbotic Inc. (NASDAQ:SYM) - Defense World

Sep 23, 2024
pulisher
Sep 21, 2024

Symbotic (NASDAQ:SYM) Shares Up 2.1% - Defense World

Sep 21, 2024
pulisher
Sep 20, 2024

Arm Joins the PHLX Semiconductor Sector Index℠ (SOX℠) - sharewise

Sep 20, 2024
pulisher
Sep 19, 2024

The Principles of Low-Carbon Tectonics: As Lygos, Pyran accelerate, we look at the why, the where, and the when - Biofuels Digest

Sep 19, 2024
pulisher
Sep 19, 2024

Symbotic (NASDAQ:SYM) Shares Gap Up to $22.41 - Defense World

Sep 19, 2024
pulisher
Sep 18, 2024

Quarterly Metrics: Quick and Current Ratios for Symbotic Inc (SYM) - The Dwinnex

Sep 18, 2024
pulisher
Sep 18, 2024

Wall Street analysts’ outlook for Symbotic Inc (SYM) - SETE News

Sep 18, 2024
pulisher
Sep 17, 2024

Understanding the Risks of Investing in Syros Pharmaceuticals Inc. (SYRS) - Knox Daily

Sep 17, 2024
pulisher
Sep 17, 2024

Siyata Mobile Inc (SYTA) expanding its growth trajectory ahead - SETE News

Sep 17, 2024
pulisher
Sep 17, 2024

What is the investor’s view on Syros Pharmaceuticals Inc. (SYRS)? - US Post News

Sep 17, 2024
pulisher
Sep 14, 2024

Syros Pharmaceuticals Chief Financial Officer Acquires 407% More Stock - Simply Wall St

Sep 14, 2024
pulisher
Sep 13, 2024

Syros Pharmaceuticals Inc. [SYRS] Shares Fall Approximately -60.45% Over the Year - Knox Daily

Sep 13, 2024
pulisher
Sep 13, 2024

Syros Pharmaceuticals Inc.’s Shares Reel: -70.93% Quarterly Revenue Decline Amid 41.97M Market Cap - The InvestChronicle

Sep 13, 2024
pulisher
Sep 13, 2024

Syros pharmaceuticals CEO buys shares worth over $160k By Investing.com - Investing.com Australia

Sep 13, 2024

Syros Pharmaceuticals Inc (SYRS) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading

Syros Pharmaceuticals Inc (SYRS) インサイダートレーディング

インサイダートレーディング 関係 日付 取引 コスト #株式 値 ($) #株式総数
Haas Jason
Chief Financial Officer
Sep 12 '24
Buy
1.68
45,344
76,006
124,552
Chee Conley
President & CEO
Sep 10 '24
Buy
1.51
50,000
75,260
72,504
Haas Jason
Chief Financial Officer
Sep 10 '24
Buy
1.55
35,363
54,788
59,915
Haas Jason
Chief Financial Officer
Sep 11 '24
Buy
1.58
19,293
30,446
79,208
Young Richard A
Director
Jun 28 '24
Sale
5.12
34,837
178,365
8,000
Roth David
Chief Medical Officer
Apr 03 '24
Sale
4.95
10,451
51,732
0
Roth David
Chief Medical Officer
Apr 02 '24
Sale
4.98
150
747
10,451
AKKARAJU SRINIVAS
Director
Dec 21 '23
Buy
4.42
904,977
3,999,998
1,786,427
Roth David
Chief Medical Officer
Dec 12 '23
Sale
4.95
6,287
31,121
0
Roth David
Chief Medical Officer
Dec 06 '23
Sale
3.95
6,287
24,834
6,287
$77.28
price up icon 2.02%
$20.39
price up icon 2.15%
$382.77
price up icon 1.58%
$53.29
price down icon 0.47%
$208.03
price up icon 0.38%
$110.97
price up icon 1.84%
大文字化:     |  ボリューム (24 時間):